Viking Global Investors invests in the Fred Hutchinson Cancer Research Centre oncology spin-out Adaptive.
US-based oncology firm Adaptive Biotechnologies has secured a $105m investment in combined series C and D rounds, both led by US-based Viking Global Investors, a privately owned hedge fund sponsor. The series C round consists of $20m, $5m of which came from Viking Global Investors, while the series D round consists of $100m. Viking Global Investors is also taking an advisory position on Adaptive’s board.
Previously, Adaptive Biotechnologies was awarded a $2.53m grant by the National Heart, Lung, and Blood…
